Literature DB >> 10768932

Candida albicans and Candida krusei differentially induce human blood mononuclear cell interleukin-12 and gamma interferon production.

J Xiong1, K Kang, L Liu, Y Yoshida, K D Cooper, M A Ghannoum.   

Abstract

Protection against Candida infection involves both innate and acquired immune responses, and cytokines produced by monocytes during the innate response may modify the acquired immune response by T cells. We hypothesized that Candida species which differ in pathogenicity can differentially induce production of immunoregulatory cytokines by human monocytes, which in turn modify T cells for immune responses to Candida. To test this hypothesis, we examined the effects of Candida albicans and Candida krusei on immunoregulatory cytokine production by human monocytes and gamma interferon (IFN-gamma) production by peripheral blood mononuclear cells (PBMC). Purified monocytes were incubated with live or heat-killed strains of C. albicans and C. krusei at the optimal Candida/monocyte ratio of 0.5. Cytokines in the supernatants were measured by enzyme-linked immunosorbent assay. Our data demonstrated that live C. albicans and C. krusei significantly induced interleukin-10 (IL-10), monocyte chemotactic factor 1, IL-1beta, and tumor necrosis factor alpha production by monocytes relative to unstimulated monocytes. In contrast, unlike C. krusei, pathogenic live strains of C. albicans induced no or only a minimal level of IL-12. The expression of IL-12 p40 mRNA levels by reverse transcription-PCR corroborated the IL-12 protein (p70) findings. In human PBMC, human blood monocytes were the major source of both IL-10 and IL-12 production in response to C. albicans and C. krusei. Upon activation of T cells in the presence of Candida-modified monocytes and antigen-presenting cells, IL-12 production by PBMC treated with Candida organisms correlated strongly with the level of IFN-gamma production by T cells. These results indicate that the virulence of C. albicans may be related to its ability to induce the monocytic type II cytokine IL-10, with a selective inhibition of IL-12 production, which may be responsible for the observed lack of T-cell IFN-gamma and may restrain an effective type I immune response to Candida.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768932      PMCID: PMC97447          DOI: 10.1128/IAI.68.5.2464-2469.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.

Authors:  J R Wingard; W G Merz; M G Rinaldi; T R Johnson; J E Karp; R Saral
Journal:  N Engl J Med       Date:  1991-10-31       Impact factor: 91.245

2.  Epidemiology of nosocomial fungal infections.

Authors:  S K Fridkin; W R Jarvis
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

3.  Differential effect of IL-10 on dendritic cell-induced T cell proliferation and IFN-gamma production.

Authors:  S E Macatonia; T M Doherty; S C Knight; A O'Garra
Journal:  J Immunol       Date:  1993-05-01       Impact factor: 5.422

4.  Tumor necrosis factor induction by Candida albicans from human natural killer cells and monocytes.

Authors:  J Y Djeu; D K Blanchard; A L Richards; H Friedman
Journal:  J Immunol       Date:  1988-12-01       Impact factor: 5.422

5.  Neutrophil oxidative burst in response to blastoconidia and pseudohyphae of Candida albicans: augmentation by granulocyte colony-stimulating factor and interferon-gamma.

Authors:  E Roilides; K Uhlig; D Venzon; P A Pizzo; T J Walsh
Journal:  J Infect Dis       Date:  1992-09       Impact factor: 5.226

6.  CD4+ subset expression in murine candidiasis. Th responses correlate directly with genetically determined susceptibility or vaccine-induced resistance.

Authors:  L Romani; A Mencacci; E Cenci; R Spaccapelo; P Mosci; P Puccetti; F Bistoni
Journal:  J Immunol       Date:  1993-02-01       Impact factor: 5.422

7.  Experimental hematogenous candidiasis caused by Candida krusei and Candida albicans: species differences in pathogenicity.

Authors:  E Anaissie; R Hachem; C K-Tin-U; L C Stephens; G P Bodey
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

Review 8.  Interleukin-10.

Authors:  K W Moore; A O'Garra; R de Waal Malefyt; P Vieira; T R Mosmann
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

9.  Interferon-gamma activates the oxidative killing of Candida albicans by human granulocytes.

Authors:  A Stevenhagen; R van Furth
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

10.  Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.

Authors:  R de Waal Malefyt; J Abrams; B Bennett; C G Figdor; J E de Vries
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

View more
  11 in total

1.  Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice.

Authors:  J Brieland; D Essig; C Jackson; D Frank; D Loebenberg; F Menzel; B Arnold; B DiDomenico; R Hare
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 2.  Candida and invasive candidiasis: back to basics.

Authors:  C S-Y Lim; R Rosli; H F Seow; P P Chong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-05       Impact factor: 3.267

3.  Hyphae and yeasts of Candida albicans differentially regulate interleukin-12 production by human blood monocytes: inhibitory role of C. albicans germination.

Authors:  L Liu; K Kang; M Takahara; K D Cooper; M A Ghannoum
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

4.  Response to oxidative stress in eight pathogenic yeast species of the genus Candida.

Authors:  Maxwel Adriano Abegg; Paulo Vinicius Gil Alabarse; Anderson Casanova; Jaqueline Hoscheid; Tiago Boeira Salomon; Fernanda Schäfer Hackenhaar; Tássia Machado Medeiros; Mara Silveira Benfato
Journal:  Mycopathologia       Date:  2010-03-13       Impact factor: 2.574

Review 5.  Interplay between Candida albicans and the mammalian innate host defense.

Authors:  Shih-Chin Cheng; Leo A B Joosten; Bart-Jan Kullberg; Mihai G Netea
Journal:  Infect Immun       Date:  2012-01-17       Impact factor: 3.441

6.  The Pathophysiology and Treatment of Candida Sepsis.

Authors:  Brad Spellberg; John E. Edwards
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

7.  Inhibition of monocytic interleukin-12 production by Candida albicans via selective activation of ERK mitogen-activated protein kinase.

Authors:  Ningfeng Tang; Liming Liu; Kefei Kang; Pranab K Mukherjee; Masakazu Takahara; Guofen Chen; Thomas S McCormick; Kevin D Cooper; Mahmoud Ghannoum
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

8.  Isolation and identification of Candida species in patients with orogastric cancer: susceptibility to antifungal drugs, attributes of virulence in vitro and immune response phenotype.

Authors:  Lourimar Viana Nascimento F de Sousa; Vera Lúcia Santos; Andrea de Souza Monteiro; Marcus Vinicíus Dias-Souza; Sirlei Garcia Marques; Elaine Speziali de Faria; Elaine Alves de Oliveira Assunção; Simone Gonçalves Dos Santos; Juan Moises Zonis; Daniel Gomes de Alvarenga; Rodrigo Assunção de Holanda; Jaqueline Gontijo de Sousa; Kênia Valéria Dos Santos; Maria Aparecida de Resende Stoianoff
Journal:  BMC Infect Dis       Date:  2016-02-23       Impact factor: 3.090

Review 9.  Immunopathology of Recurrent Vulvovaginal Infections: New Aspects and Research Directions.

Authors:  Namarta Kalia; Jatinder Singh; Manpreet Kaur
Journal:  Front Immunol       Date:  2019-08-28       Impact factor: 7.561

10.  Proinflammatory profile of in vitro monocytes in the ageing is affected by lymphocytes presence.

Authors:  Karen Henriette Pinke; Bruno Calzavara; Patricia Freitas Faria; Magda Paula Pereira do Nascimento; James Venturini; Vanessa Soares Lara
Journal:  Immun Ageing       Date:  2013-06-08       Impact factor: 6.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.